Andreas and Thomas Strüngmann (via Agreus Group)
December 10, 2021 07:14 AM ESTUpdated 11:34 AM
Deals
Bioregnum

Bil­lion­aire BioN­Tech back­ers have been kick­ing the tires at No­var­tis' big gener­ics arm — re­port

While the ul­ti­mate fate of No­var­tis’ big gener­ics arm San­doz may still be up in the air, there’s no doubt it’s in play as a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times